This Company Gave Away a Drug That Just Won the Nobel Prize and Helped Millions

Big Pharma helped these scientists to eliminate two horrible diseases.

<a href="http://www.shutterstock.com/cat.mhtml?lang=en&language=en&ref_site=photo&search_source=search_form&version=llv1&anyorall=all&safesearch=1&use_local_boost=1&autocomplete_id=ifejr01jlwpsj18au2m&search_tracking_id=6y7sOLVyfKXO5xY_Hj2Tsg&searchterm=pharmaceutical&show_color_wheel=1&orient=&commercial_ok=&media_type=images&search_cat=&searchtermx=&photographer_name=&people_gender=&people_age=&people_ethnicity=&people_number=&color=&page=1&inline=161761511">Kaesler Media</a>/Shutterstock

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


Earlier today, the Nobel committee awarded its renowned prize for medicine to the discoverers of two anti-parasitic drugs — one that fights malaria and one that treats two lesser-known devastating diseases.

The latter, ivermectin, treats lymphatic filariasis and river blindness, which are parasites that have plagued humans for centuries and currently threaten 1.35 billion people around the world. Developing drugs to treat infectious diseases and making them available to the often-impoverished people who need them is extremely difficult. But because of a breakthrough and an unprecedented move by one of the largest pharmaceutical companies in the world, these diseases might soon be eradicated.

Satoshi Omura Kyodo/AP

Lymphatic filariasis, which can develop into a condition known as elaphantiasis, is a mosquito-transmitted worm that lodges in the lymphatic system, impairing it along with the victim’s immune system and kidneys. In the worst cases, the worm causes extreme swelling and disfigurement of tissue, limbs, and genital parts. According to the World Health Organization (WHO) 40 million people, mostly in African and South Asian countries are incapacitated by the disease, and shunned because of their disfigurement.

Onchocerciasis, or river blindness, is a worm spread through the bite of a blackfly, which breeds in rivers. The parasite produces larvae that move through human tissue, causing sever itching and skin rashes, as well as eye lesions, which can lead to severe visual impairment. An estimated 270,000 people are currently blinded by the disease. The vast majority of people at-risk live in Africa, where it has taken a huge economic toll on rural communities, which have had to move away from rivers to less productive land in order to avoid the disease.

William Campbell Mary Schwalm/AP

In the late 1970s, Satoshi Omura, a scientist at the Kitasato Institute in Tokyo found a component of a soil-dwelling bacteria (that’s right, he literally found it in the dirt) called Streptomyces that was very effective at killing parasites. He then sent cultures of this bacteria to William Campbell in New Jersey who worked for Merck & Co., the fourth largest pharmaceutical company in the world. There, Campbell successfully developed a drug called ivermectin from a compound in the bacteria culture. The discovery was a huge pharmaceutical breakthrough and the drug was determined to be extremely safe for humans and easily distributed.

But, as with many infectious disease drugs, the vast majority of people who needed it lived in the developing world and could not afford it.

What happened next was unprecedented.

In 1987, Merck announced it would partner with the WHO and donate Mectizan, the drug’s brand name, to any country who requested it for as long as they needed it. Before this, no large pharmaceutical company had ever given away a drug they developed to eradicate a disease. At a news conference after Merck’s announcement, the late Massachusetts senator Ted Kennedy said, “Merck’s gift to the World Health Organization is more than a medical breakthrough–it is truly a triumph of the human spirit.”

Since 1987, the Mectizan Donation Program has given out more than a billion treatments for onchoceriasis and lymphatic filariasis to people in 33 countries (in the late ’90s GlaxoSmithKline contributed another drug for lymphatic filariasis to the program). As a result, the transmission of onchoceriasis has been stopped in many countries. Last year Ecuador became the second affected country, after Colombia, to entirely eradicate the disease. Lymphatic filariasis cases have dramatically decreased, as well. The WHO forecasts that both diseases could be eliminated by 2020.

Omura and Campbell were awarded the Nobel Prize in medicine for their work.

The Nobel committee said ivermectin’s importance was “immeasurable” for the health of many in the world’s poorest regions.

“Treatment is so successful that these diseases are on the verge of eradication, which would be a major feat in the medical history of humankind,” the committee said.

AN IMPORTANT UPDATE

We’re falling behind our online fundraising goals and we can’t sustain coming up short on donations month after month. Perhaps you’ve heard? It is impossibly hard in the news business right now, with layoffs intensifying and fancy new startups and funding going kaput.

The crisis facing journalism and democracy isn’t going away anytime soon. And neither is Mother Jones, our readers, or our unique way of doing in-depth reporting that exists to bring about change.

Which is exactly why, despite the challenges we face, we just took a big gulp and joined forces with The Center for Investigative Reporting, a team of ace journalists who create the amazing podcast and public radio show Reveal.

If you can part with even just a few bucks, please help us pick up the pace of donations. We simply can’t afford to keep falling behind on our fundraising targets month after month.

Editor-in-Chief Clara Jeffery said it well to our team recently, and that team 100 percent includes readers like you who make it all possible: “This is a year to prove that we can pull off this merger, grow our audiences and impact, attract more funding and keep growing. More broadly, it’s a year when the very future of both journalism and democracy is on the line. We have to go for every important story, every reader/listener/viewer, and leave it all on the field. I’m very proud of all the hard work that’s gotten us to this moment, and confident that we can meet it.”

Let’s do this. If you can right now, please support Mother Jones and investigative journalism with an urgently needed donation today.

payment methods

AN IMPORTANT UPDATE

We’re falling behind our online fundraising goals and we can’t sustain coming up short on donations month after month. Perhaps you’ve heard? It is impossibly hard in the news business right now, with layoffs intensifying and fancy new startups and funding going kaput.

The crisis facing journalism and democracy isn’t going away anytime soon. And neither is Mother Jones, our readers, or our unique way of doing in-depth reporting that exists to bring about change.

Which is exactly why, despite the challenges we face, we just took a big gulp and joined forces with The Center for Investigative Reporting, a team of ace journalists who create the amazing podcast and public radio show Reveal.

If you can part with even just a few bucks, please help us pick up the pace of donations. We simply can’t afford to keep falling behind on our fundraising targets month after month.

Editor-in-Chief Clara Jeffery said it well to our team recently, and that team 100 percent includes readers like you who make it all possible: “This is a year to prove that we can pull off this merger, grow our audiences and impact, attract more funding and keep growing. More broadly, it’s a year when the very future of both journalism and democracy is on the line. We have to go for every important story, every reader/listener/viewer, and leave it all on the field. I’m very proud of all the hard work that’s gotten us to this moment, and confident that we can meet it.”

Let’s do this. If you can right now, please support Mother Jones and investigative journalism with an urgently needed donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate